
-
Adial Pharmaceuticals NasdaqCM:ADIL Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Location: 4870 Sadler Road, Glen Allen, VA, 23060, United States | Website: https://www.adial.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.046M
Cash
2.366M
Avg Qtr Burn
-1.72M
Short % of Float
4.91%
Insider Ownership
1.16%
Institutional Own.
7.27%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AD04 Details Alcohol use disorder | Phase 3 Initiation | |
ADO-5030 Details Asthma | Phase 1 Data readout |